AbbVie Inc. vs General Motors Company: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and General Motors Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating General Motors Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and General Motors Company is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $185.0B for General Motors Company, while their respective market capitalizations stand at $465.8B and $74.9B. Both AbbVie Inc. and General Motors Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics.

General Motors Company: General Motors (NYSE: GM) is the largest U.S. automaker by sales, with 2.85 million U.S. deliveries and about a 17% market share in 2025. Based in Detroit, it sells vehicles under Chevrolet, GMC, Cadillac, and Buick, and runs GM Financial for auto loans and leases. Its identity today is tied to profitable pickups such as the Silverado and Sierra and large SUVs such as the Escalade, which fund a slower-than-planned move into EVs, software, and driver assistance.

AbbVie Inc. and General Motors Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and General Motors Company.

AbbVie Inc. business model: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.

General Motors Company business model: GM makes money mainly by building and wholesaling vehicles to its dealer network, then earning a second layer of profit through GM Financial, its captive lender. GM North America (GMNA) is the profit engine: full-size pickups such as the Chevrolet Silverado and GMC Sierra and large SUVs such as the Tahoe, Suburban, Yukon, and Cadillac Escalade carry far higher margins than small cars or current EVs. GM International covers markets such as South America, South Korea, and the Middle East, while China is run through joint ventures (notably SAIC-GM) whose results show up as equity income rather than consolidated revenue. GM Financial earns interest and lease income from retail loans, leases, and dealer floorplan lines that also help move GM inventory. A smaller but growing layer of recurring revenue comes from software and services such as OnStar and the Super Cruise hands-free driving system. GM sold Opel/Vauxhall to PSA in 2017 and stopped selling vehicles in India the same year, so its footprint is now concentrated on North America.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of General Motors Company.

AbbVie Inc. competitive advantage: AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.

General Motors Company competitive advantage: GM's clearest advantage is scale in U.S. full-size pickups and SUVs: it has led the full-size pickup segment for six straight years, selling about 940,000 in 2025. That franchise, a national Chevrolet, GMC, Buick, and Cadillac dealer network, and GM Financial's captive lending give it cash flow and pricing power that newer EV-only rivals do not have. Super Cruise and OnStar give it a software and services base that competitors are still building.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and General Motors Company each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

General Motors Company growth strategy: GM's growth strategy has shifted from an all-EV push to flexibility. It still sells EVs on its Ultium-based platforms, such as the Chevrolet Equinox EV and Cadillac Lyriq, but after 2025 it cut EV capacity, kept investing in gas trucks and SUVs, and plans lower-cost lithium manganese-rich (LMR) cells with LG Energy Solution. In December 2024 GM stopped funding the Cruise robotaxi business and folded that work into its own engineering team. Growth now rests on software and services (OnStar, Super Cruise, and a planned eyes-off driving system), plus disciplined pricing and inventory.

A closer look at the financial trajectory of AbbVie Inc. and General Motors Company rounds out the comparison.

AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.

General Motors Company: GM's finances are funded by internal-combustion trucks and SUVs. In 2025 it generated $185.0 billion of revenue, $12.7 billion of EBIT-adjusted, and $10.6 billion of adjusted automotive free cash flow, but EV write-downs cut net income attributable to stockholders 55% to $2.7 billion. Q1 2026 revenue was $43.6 billion with $2.6 billion of net income; Q2 2026 revenue was $48.0 billion with $1.3 billion of net income, $3.9 billion of EBIT-adjusted, and North America margins back inside GM's 8-10% target. GM returns large amounts of cash to shareholders and approved a new $6.0 billion buyback alongside a 20% higher quarterly dividend in January 2026.